Diamond Member Pelican Press 0 Posted September 12, 2024 Diamond Member Share Posted September 12, 2024 This is the hidden content, please Sign In or Sign Up Gilead Lenacapavir cut **** infections by 96% in trial A pharmacist holds a vial of lenacapavir, the new **** prevention injectable *****. Nardus Engelbrecht | AP Gilead‘s twice-yearly shot reduced **** infections by 96% in a second large study, the company said Thursday. The positive phase three trial data on Lenacapavir sets the stage for likely approval by the U.S. Food and ***** Administration for **** prevention. “Now that we have a comprehensive dataset across multiple study populations, Gilead will work urgently with regulatory, government, public health and community partners to ensure that, if approved, we can deliver twice-yearly lenacapavir for PrEP worldwide, for all those who want or need PrEP,” said Gilead CEO Daniel O’Day in a statement. PrEP or, pre-exposure prophylaxis, is a medication taken to prevent getting ****, according to the Centers for ******** Control and Prevention. Gilead shares climbed about 3% in premarket trading Thursday. The company said 99.9% of participants who received Lenacapavir did not acquire ****, with two cases among 2,180 people. The trial included cisgender men, transgender men, transgender women and gender non-binary people who have **** with partners assigned male at birth. This is the hidden content, please Sign In or Sign Up This is the hidden content, please Sign In or Sign Up #Gilead #Lenacapavir #cut #**** #infections #trial This is the hidden content, please Sign In or Sign Up This is the hidden content, please Sign In or Sign Up 0 Quote Link to comment https://hopzone.eu/forums/topic/124602-gilead-lenacapavir-cut-hiv-infections-by-96-in-trial/ Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.